Nonalcoholic Steatohepatitis (NASH) Treatment Market is expected to grow at 38% by 2031. Nonalcoholic steatohepatitis (NASH) is also known as ‘fatty liver’ a disorder that develops in patients who are not alcoholic; mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to poor understanding of pathogenesis linked to insulin resistance especially in obesity or metabolic syndrome. Market experts suggest that most of the patients are asymptomatic and laboratory findings related with NASH mainly include elevations in aminotransferase levels. However, in diagnosis of NASH biopsy pays key role in diagnosis. According to American Liver Foundation, NASH is the third leading cause of liver transplant in the U.S.; database suggests more than 12% of the general population has NASH and approximately 2.7% have advanced liver fibrosis due to the disease. NASH comprises treatment of obesity, insulin-sensitizing agents, lipid-lowering agents, antioxidants, and hepatoprotective therapy. In NASH treatment weight reduction has been widely studied in adults and has shown improvement not only the biochemical results but also the histology.
According to Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events and currently it cannot be recommended for NAFLD. In case of insulin - sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (thioglitazones) have projected improvement in insulin resistance, by acting as surrogate marker of fatty liver, and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the “Chilean Gastroenterological Society” and the “Chilean Hepatology Association” suggested that pioglitazone along with vitamin E is a proven pharmacological choice for patients with biopsy-proven NASH, however evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.
North America was observed as the largest market for NASH treatment followed by Europe. In North America, the rising prevalence of obesity, and the increasing incidence of diabetes are the key factors assisting the NASH treatment market. According to Cleveland Clinic, The prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population. The prevalence is increased in men, older individuals (those aged 40-70 years), and those with components of the metabolic syndrome especially diabetes and abdominal obesity. The prevalence of childhood obesity and non-alcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups with the highest prevalence seen in Hispanics compared with Caucasians and African Americans Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
According to Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events and currently it cannot be recommended for NAFLD. In case of insulin - sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (thioglitazones) have projected improvement in insulin resistance, by acting as surrogate marker of fatty liver, and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the “Chilean Gastroenterological Society” and the “Chilean Hepatology Association” suggested that pioglitazone along with vitamin E is a proven pharmacological choice for patients with biopsy-proven NASH, however evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.
North America was observed as the largest market for NASH treatment followed by Europe. In North America, the rising prevalence of obesity, and the increasing incidence of diabetes are the key factors assisting the NASH treatment market. According to Cleveland Clinic, The prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population. The prevalence is increased in men, older individuals (those aged 40-70 years), and those with components of the metabolic syndrome especially diabetes and abdominal obesity. The prevalence of childhood obesity and non-alcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups with the highest prevalence seen in Hispanics compared with Caucasians and African Americans Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period.
Key Players Identified for Non-Alcoholic Steatohepatitis (NASH) Treatment Market Include but are Not Limited to:
- Intercept Pharmaceutical.- Galmed Pharmaceutical.
- Inventiva Pharm.
- AbbVie Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceutical.
- NGM Biopharmaceuticals Inc.
- Novo Nordisk A/.
- Bristol Myers Squib.
- Gilead Sciences Inc.
Historical & Forecast Period
This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review.A key data point that enables the estimation of Nonalcoholic Steatohepatitis (NASH) Treatment market are as follows.- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Nonalcoholic Steatohepatitis (NASH) Treatment market and their expected impact during the forecast period.
Segmentation
Drug Type
- Vitamin E and Pioglitazone
- Obeticholic Acid (OCA)
- Lanifibranor
- Semaglutide
- Resmetirom
- Aramchol
- Cenicriviroc
- Others
End-use
- Hospital Pharmacies
- Retail & Specialty Pharmacies
- Others
Region Segment (2021 - 2031; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Nonalcoholic Steatohepatitis (NASH) Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Nonalcoholic Steatohepatitis (NASH) Treatment market?
- Which is the largest regional market for Nonalcoholic Steatohepatitis (NASH) Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Nonalcoholic Steatohepatitis (NASH) Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Nonalcoholic Steatohepatitis (NASH) Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Competitive Analysis
4. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Macro Analysis & Market Dynamics
5. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
6. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
7. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)
8. UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)
9. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)
10. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)
11. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)
12. Company Profile
List of Figures
List of Tables
Companies Mentioned
- Intercept Pharmaceuticals
- Galmed Pharmaceuticals
- Inventiva Pharma
- AbbVie Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals
- NGM Biopharmaceuticals Inc.
- Novo Nordisk A/S
- Bristol Myers Squibb
- Gilead Sciences Inc.
